67765-42-8

Basic information

• Product Name: 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione
• Synonyms: 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione;5-Methoxy-2H-3,1-benzoxazine-2,4(1H)-dione, 5-Methoxy-1H-benzo[d][1,3]oxazine-2,4-dione;2H-3,1-Benzoxazine-2,4(1H)-dione, 5-Methoxy-;6-Methoxyisatoic anhydride
• CAS NO: 67765-42-8
• Molecular Formula: C₉H₇NO₄
• Molecular Weight: 193
• Mol File: 67765-42-8.mol
• Article Data: 24

Chemical Properties

• Melting Point: 258-261 °C
• Appearance: /
• Density: 1.376±0.06 g/cm3(Predicted)
• Storage Temp.: Sealed in dry,Room Temperature
• PKA: 10.31±0.20(Predicted)
• CAS DataBase Reference: 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione(CAS DataBase Reference)
• NIST Chemistry Reference: 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione(67765-42-8)
• EPA Substance Registry System: 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione(67765-42-8)

Safety Data

• Hazardous Substances Data: 67765-42-8(Hazardous Substances Data)

Usage

General Description

5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione is a chemical compound characterized as a benzo[d][1,3]oxazine-2,4-dione derivative that contains a methoxy group at the 5 position. It is a heterocyclic compound that is commonly used as a building block in organic synthesis and pharmaceutical research. 5-methoxy-1H-benzo[d][1,3]oxazine-2,4-dione has been studied for its potential pharmacological properties, including its role as an anticoagulant and its ability to act as a ligand for various biological receptors. Its chemical structure and properties make it a valuable tool in the development of new drugs and compounds for medical and research purposes.

Upstream product

• 14963-96-3 3-methoxyphthalic anhydride 
• 53600-33-2 6-methoxyanthranilic acid 
• 76-02-8 trifluoroacetyl chloride 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 136247-94-4 N-(tert-butoxycarbonyl)-6-methoxyanthranilic acid 
• 536-90-3 m-Anisidine 
• 60144-52-7 tert-butyl 3-methoxyphenylcarbamate 
• 75-44-5 phosgene 

Downstream Products

• 76746-20-8 2-Amino-6-methoxy-benzoic acid hydrazide 
• 254964-60-8 1,2-dihydro-4-hydroxy-5-methoxy-N,1-dimethyl-2-oxo-N-[4-(trifluoromethyl)phenyl]-3-quinolinecarboxamide 
• 248282-13-5 1,2-dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxylic acid ethyl ester 
• 248282-18-0 1,2-Dihydro-4-hydroxy-5-methoxy-1-methyl-2-oxo-quinoline-3-carboxylic acid 
• 943138-88-3 C₂₁H₂₄FNO₇S 
• 955937-60-7 C₂₂H₂₆FNO₇S 

Relevant articles and documents

MODIFIED PROTEINS AND PROTEIN DEGRADERS

Provided herein are compounds, pharmaceutical compositions, and methods for binding or degrading target proteins. Further provided herein are compounds having a DNA damage-binding protein 1 (DDB1) binding moiety. Some such embodiments include a linker. Some such embodiments include a target protein binding moiety. Further provided herein are ligand-DDB1 complexes. Further provided herein are in vivo modified DDB1 proteins.

Discovery of Evodiamine Derivatives as Highly Selective PDE5 Inhibitors Targeting a Unique Allosteric Pocket

Clinical use of phosphodiesterase-5 (PDE5) inhibitors is limited by several side effects due to weak isoform selectivity. Herein, a unique allosteric pocket of PDE5 is identified by molecular modeling and structural biology, which enables the discovery of highly selective PDE5 inhibitors from natural product evodiamine (EVO). The crystal structure of PDE5 with bound EVO derivative (S)-7e revealed that binding of (S)-7e to the novel allosteric pocket induced dramatic conformation changes in the H-loop with a maximum 24 ? movement of their Cα atoms. This movement directly blocks the binding of substrate/inhibitors to the PDE5 active site, which is different from all traditional PDE5 inhibitors such as sildenafil, tadalafil, and vardenafil. These derivatives showed >570-fold selectivity over PDE6C and PDE11A and achieved potent efficacy for the effective treatment of pulmonary hypertension in vivo.

Evodiamine compounds and preparation method and application thereof

The invention discloses evodiamine compounds and a preparation method and application thereof. The evodiamine compounds adopt structures shown as a general formula (I), and comprise racemates, d-type or l-type isomers and pharmaceutically acceptable salts thereof. Pharmacological tests prove that the evodiamine compounds have obvious phosphodiesterase PDE5 inhibiting activity, some of the evodiamine compounds have equivalent PDE5 inhibiting activity to sildenafil, and the evodiamine compounds have stronger phosphodiesterase PDE6 selectivity. The evodiamine compounds can be clinically used for improving or treating symptoms or diseases in a cardiovascular system, a cerebrovascular system and a urinary system, especially improving or treating symptoms or diseases including erectile dysfunction and pulmonary hypertension.